Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile

Jens Benn Sørensen; Eric Santoni-Rugiu; Edyta Maria Urbanska

doi:10.21037/cco-24-19

Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile

Jens Benn Sørensen^*, Eric Santoni-Rugiu, Edyta Maria Urbanska

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Leder › Forskning › peer review

Originalsprog	Engelsk
Artikelnummer	88
Tidsskrift	Chinese Clinical Oncology
Vol/bind	13
Udgave nummer	6
Antal sider	4
ISSN	2304-3865
DOI	https://doi.org/10.21037/cco-24-19
Status	Udgivet - 2024

Adgang til dokumentet

10.21037/cco-24-19Licens: CC BY-NC-ND

FulltextForlagets udgivne version, 138 KBLicens: CC BY-NC-ND

Citationsformater

Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile. / Sørensen, Jens Benn ; Santoni-Rugiu, Eric; Urbanska, Edyta Maria.

I: Chinese Clinical Oncology, Bind 13, Nr. 6, 88, 2024.

Publikation: Bidrag til tidsskrift › Leder › Forskning › peer review

@article{144ab196a02b4f3d9a973083e1046251,

title = "Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile",

keywords = "befotertinib, epidermal growth factor receptor-mutations (EGFR-mutations), epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), Non-small cell lung cancer (NSCLC)",

author = "S{\o}rensen, {Jens Benn} and Eric Santoni-Rugiu and Urbanska, {Edyta Maria}",

year = "2024",

doi = "10.21037/cco-24-19",

language = "English",

volume = "13",

journal = "Chinese Clinical Oncology",

issn = "2304-3865",

publisher = "Society for Translational Medicine (STM)",

number = "6",

}

TY - JOUR

T1 - Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile

AU - Sørensen, Jens Benn

AU - Santoni-Rugiu, Eric

AU - Urbanska, Edyta Maria

PY - 2024

Y1 - 2024

KW - befotertinib

KW - epidermal growth factor receptor-mutations (EGFR-mutations)

KW - epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)

KW - Non-small cell lung cancer (NSCLC)

U2 - 10.21037/cco-24-19

DO - 10.21037/cco-24-19

M3 - Editorial

C2 - 39260433

AN - SCOPUS:85213289506

VL - 13

JO - Chinese Clinical Oncology

JF - Chinese Clinical Oncology

SN - 2304-3865

IS - 6

M1 - 88

ER -